{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'PRINCIPAL INVESTIGATOR SIGNATURE PAGE', 'Protocol Number:', 'HZNP-TEP-301', 'Version:', '4.0, incorporating Amendment 3', 'Protocol Title:', 'A Phase 3, Randomized, Double-Masked, Placebo-Controlled,', 'Parallel-Group, Multicenter Study Evaluating Teprotumumab (HZN-001)', 'Treatment in Subjects with Active Thyroid Eye Disease (OPTIC)', 'Version Date:', '31 January 2019', 'I agree to conduct the study according to the protocol named above. I fully understand that any', 'changes instituted by the Principal Investigator without previous discussion with the Sponsor', 'constitute a violation of the protocol, unless necessary to eliminate an immediate hazard to the', 'safety or well-being of a subject.', 'I acknowledge that I have read and understand the protocol named above and agree to carry out', 'all of its terms in accordance with applicable regulations and laws.', 'I assure that the study drug supplied by the Sponsor will be used only as described in the', 'protocol named above.', 'Signature:', 'Name', 'Date', 'Study Center', 'Address', 'City State Country', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 4 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'SUMMARY OF CHANGES', 'Protocol HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'Version 3.0 of the protocol, which was approved 16 April 2018, has been amended to', 'incorporate the changes of Amendment 3.', 'Add diplopia responder rate (defined as the percentage of subjects with baseline diplopia', '0 in study eye who have a reduction of > 1 grade with no corresponding deterioration', '1 grade worsening] in the fellow eye at Week 24) as a secondary endpoint.', 'Add 2 additional follow-up contacts (telephone or email) at 6 and 12 months after the', 'Week 72 Visit to assess any additional thyroid eye disease (TED) treatment received', 'since last study contact.', 'Clarify that female subjects of childbearing potential who are sexually active with a', 'non-vasectomized male partner must agree to use 2 reliable forms of contraception, one', 'of which is recommended to be hormonal, during the trial and for 180 days after the last', 'dose of study drug.', 'Clarify that male subjects who are sexually active with a female partner of childbearing', 'potential must agree to use a barrier contraceptive method from Screening through', '180 days after the last dose of study drug.', 'Change the number of teprotumumab doses that will be administered in the open-label', 'extension study (HZNP-TEP-302) from \"up to 8\" to \\'8\\'.', 'Clarify that Clinical Activity Score (CAS) criteria for determining relapse refers only to', 'the study eye.', 'Amend the CAS relapse criterion to include an increase in CAS of > 2 points since', 'Week 24 with an absolute CAS > 4 following the Week 24 Visit.', 'Specify the minimum duration of study drug infusions.', 'Clarify that the weight obtained at Week 12 can be used for the calculation of study drug', 'dose beginning at Week 12 or Week 15.', 'Remove the specified temperature collection methods (oral or tympanic).', 'Correct that the urine sample collected at Week 15 is for pregnancy testing only.', 'Change the definition of the end of the trial to date of the last subject contact at', 'Week 120.', 'Update statistical analysis methods.', 'Update Sponsor Representative title.', 'Correct minor typographical errors (changes are not detailed below).', 'The following sections of the protocol are affected: 2, 2.1, 7.1.3.4.5.5.1, 8.2, 9.1, Figure 9.1,', '9.3.1, 9.3.4, 9.4.1, 9.4.6.2, 9.4.6.3.1, 9.4.6.3.2, 9.5.1, 9.5.5.4, 9.5.5.5, 9.5.7.1, 9.5.7.2, 9.5.7.6,', '9.5.7.8, 9.5.7.9, 9.5.7.10, 9.5.7.12, 9.5.7.13, 9.5.7.14, 9.5.7.15, 9.5.7.16, 9.5.7.17, 9.5.7.18,', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 5 of 117']\n\n###\n\n", "completion": "END"}